https://www.selleckchem.com/pe....ptide/dulaglutide.ht
© 2020, Edelmaier et al.OBJECTIVE To help identify adverse events (AEs) in new biologic therapies and to spread the culture of pharmaceutical surveillance among patients affected by psoriasis or inflammatory bowel disease (IBD). MATERIALS AND METHODS This active pharmacovigilance program provided all patients with telephone follow-ups (FU), carried out by a clinical pharmacologist for a total duration of 1 year. Collected AEs were classified according to the MedDRA dictionary. RESULTS 21 patients with psoriasis and 10 patients with I
Like
Comment
Share
